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Background: Iodine interstitial brachytherapy has been widely reported for treating colorectal cancer (CRC).
However, the inhibitory molecular mechanism of iodine-125 (I-125) on CRC has not been reported.
Methods: To illustrate the inhibitory mechanism of iodine-125 (I-125) on CRC, we established the animal models of
CRC via the injection of HCT-8 cells into nude mice. Subsequently, the I-125 granules were implanted into the
tumor of the animal model at different dosages. Proliferating cell nuclear antigen and terminal transferase dUTP nick
end labeling were used to detect the apoptosis of the tumor cells. Immunohistochemistry SP staining was used to
measure the expression of p53 protein. The protein levels were examined with western blot and ELISA. Meanwhile,
microvessel density (MVD) was counted by endothelial cells immunostained by anti-CD34 antibody.
Results: The results showed that I-125 protests against CRC via increasing the protein level of p53 and decreasing
the level of vascular endothelial growth factor (VEGF), leading to the decrease of MVD in CRC (P <0.0001). An effective
inhibition dosage of I-125 ranged from 0.4 to 0.8 mCi.
Conclusions: The inhibitory mechanisms of iodine on CRC acted through an increase in the level of p53 and a
decrease in the level of VEGF, resulting in a decrease of MVD.
Keywords: Colorectal cancer, HCT-8 tumor model, I-125 interstitial brachytherapy, Microvessel density, p53 protein,
Vascular endothelial growth factorBackground
According to a previous report [1], colorectal cancer
(CRC) is the third most common cancer in men and the
second in women worldwide, with most cases occurring
in developed regions. Existing treatments are ineffective
in the cure of CRC [2]. Further, the cancer’s size and/or
position may make surgery difficult and thus patients
survive for only a short time after surgery [3]. Addition-
ally, gastrointestinal stromal tumors (GISTs), a subset of
soft tissue sarcomas, have proven to be insensitive to
chemotherapy and radiotherapy [4].
Radioactive iodine-125 (I-125) seed implantation can
improve the target volume dose with a high level of
radioactive iodine. The tumor, which is refractory and* Correspondence: yyyunnan@163.com
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unless otherwise stated.insensitive to chemotherapy and radiotherapy, can be ef-
fectively controlled via iodine treatment [5]. Further-
more, the preservation of urinary, sexual, and rectal
quality of life is excellent at long-term follow-up for the pa-
tients implanted with I-125 [6]. Iodine interstitial brachy-
therapy has been widely reported for treating CRC.
Segmental intraluminal instillation of iodine was advo-
cated to prevent anastomotic recurrence after colonic
resection for CRC [7]. Most patients with recurrent or
metastatic CRC underwent radio-immune-guided sur-
gery [8]. I-125 has also been widely applied to treat
other cancers. For instance, I-125 brachytherapy im-
plantation is a safe and effective treatment strategy for
patients with both lower urinary tract symptoms and
localized prostate cancer [9]. Combined techniques
with I-125 implant show better anti-tumor effects. Fur-
ther, the addition of external beam radiotherapy can
confer a significant biochemical control for prostate. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The patients with IS-IV (interval survival for stage IV
pancreatic cancer), received radical treatment, are sig-
nificantly longer than those who received palliative
treatment. Multiple treatments play an important role
in improving the IS-IV of patients who received radical
treatment [11].
The inhibitory molecular mechanisms of iodine on
some cancers have been reported [12-14]. However, the
inhibitory molecular mechanism of I-125 on CRC is still
widely unknown. Understanding the molecular mechan-
ism will be beneficial to make full use of the I-125
brachytherapy implant techniques effectively and safely.
CRC models with nude mice are readily available [15,16],
allowing for the exploration of the inhibitory molecular
mechanisms of I-125 on CRC. We established a CRC ani-
mal model using nude mice, followed by the implant of
the I-125 granules at different dosages. The inhibitory mo-
lecular mechanisms were explored and are described
herein.Methods
Cell culture
As previously described [17], HCT-8 cells were maintained
under serum-free conditions using McCoy’s 5A medium
supplemented with 4 μg/mL of transferrin, 5 μg/mL of in-
sulin, and 10 ng/mL of vascular endothelial growth factor
(VEGF) in a 5% CO2 at 37°C and 100% humidity, and pas-
saged every 2 or 3 days.Orthotopic implantation
All the protocols were approved by the animal care and
ethics committee of the Second People’s Hospital of
Yunnan (Kunming, China). Informed consent was ob-
tained from each patient before the study. BALB/c
nude male mice were raised in a HEPA-filtered en-
vironment. HCT-8 labeled cells were subcutaneously
injected into the mice. At 1 cm3, the xenograft was
excised and minced for implantation into other 4- to
6-week-old BALB/c nude mice. One 1 mm3 piece
per mouse was subcutaneously implanted to the axil-
lary region of 50 other BALB/c nude male mice, as
previously described [18].I-125 brachytherapy seed implant
Five days after the tumors were implanted, an I-125 seed
or an inactive sham seed was inserted into the tumor
areas of the mice model. Every 10 mice received experi-
mental seeds with the radio dosage of 0.2, 0.4, and 0.8
mCi. Ten control mice received the sham seeds or
did not receive the implant. Every 5 days, the tumor
volume was calculated using the modified ellipsoidformula 1/2 (Length × Width2). All mice were sacri-
ficed after 15 days.
The determination of p53
Immunohistochemical SP staining was used to deter-
mine the protein levels of p53 according to a previous
report [19]. Briefly, 5-μm formalin-fixed paraffin-embedded
sections from the tumors were boiled for 5 min in the pres-
ence of lead thiocyanate solution. Sections were incubated
at room temperature for 30 min with a 1:1,000 dilution of
the polyclonal antibody, CM-1 (Covance, Inc., Beijing,
China) against p53 protein after blocking endogenous
peroxidase activity with goat serum. Immunohistochemi-
cal staining was performed using the streptavidin-biotin
complex procedure according to the manufacturer’s direc-
tion (Advanced Technology & Industrial Co., Ltd., Hong
Kong). As a control, the same procedure was carried out
except that the primary antibody was replaced by PBS.
The neoplastic areas were examined for immunohisto-
chemical staining by one investigator, blinded to the p53
mutation status. Only the nuclear immunostaining was
considered as positive for p53 protein accumulation. The
level of protein accumulation was scored as 0 (no detect-
able immunostaining), 1 (few nuclei), 2 (up to 10% nuclei),
3 (10 to 50% nuclei), and 4 (>50% nuclei). The numerical
scoring was confirmed by a second independent examin-
ation, blinded to the initial score.
Proliferating cell nuclear antigen (PCNA) and terminal
transferase dUTP nick end labeling (TUNEL) assay for
apoptosis
PCNA was examined to investigate cell proliferation,
which can reflect the degree of the cellular apoptosis. All
cells were fixed in PBS formalin, embedded in paraffin
and stained. PCNA was performed using a labeled
streptavidin-biotin. Anti-PCNA monoclonal antibody
(DAKO, Carpenteria, CA, USA) reacted exclusively
with nuclei.
TUNEL was also performed to examine the apoptosis
according to a previous report [20]. All cells were sus-
pended in PBS buffer by gently vortexing the vials and
aliquoted to approximately 1 × 106 cells/mL per test.
The cells were collected via centrifuge for 5 min (300 g)
and resuspended in 1 mL of the wash buffer in each
tube. After washing three times, 50 μL of the TdT en-
zyme mixture were added to the sample and incubated
for 60 min at 37°C in a water bath. Subsequently, the cells
were washed three times and resuspended in 0.1 mL of
the antibody labeling mix. The tubes were incubated in
the dark for 30 min at room temperature. The cells were
washed three times and suspended in 0.9 mL PBS. One
hundred μL propidium iodide/RNase were added to each
tube. After 3 hours of staining, the samples were analyzed
by flow cytometry.
Figure 1 The tumor volume of nude mice model before/after
I-125 seed implant. Comparing with the control group, *P <0.001
using least significant difference method. Each bar represented the
mean ± SD of three independent experiments.
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growth factor (VEGF) and quantitation of microvessel
density (MVD)
The expression level of VEGF was determined according
to Takahashi standard [21]. Immunohistochemical ana-
lyses, using the antibodies against VEGF and PCNA,
were performed in 50 human colon carcinomas. Vessels
were quantitated by light microscopy and the intensity
of staining for VEGF was assessed on a scale of 0 to 3+.
Proliferation was determined by counting the number of
PCNA-positive cells per 500 tumor cells. The high ex-
pression of VEGF was correlated with the extent of neo-
vascularization and the degree of cellular proliferation.
MVD, a measure of angiogenesis in tumors, has been
shown to be a prognostic indicator that correlates with
an increased risk of metastasis in various cancers [22].
MVD was measured according to a previous report [23].
Western blotting analysis
After I-125 treatments with different dosages, cells were
washed in Dulbecco’s phosphate-buffered saline (DPBS)
(Life Technologies, Grand Island, USA) and incubated in
cysteine-free/methionine-free DMEM (Life Technolo-
gies, Inc.) for 30 min. One 6-cm plate containing 1 × 106
cells was used for per sample. Cell lysates were prepared
as previously described [24]. Total protein in lysates was
quantified using Bradford reagent (Bio-Rad Laboratories,
Inc., Richmond, CA, USA). All proteins were separated on
10% SDS-PAGE. Western blot analysis was conducted
with the monoclonal antibody against p53 (clone BP53-12
at a 1:50 dilution, Novocastra, Newcastle upon Tyne, UK)
and polyclonal antibody against VEGF (clone A-20 at a
1:300 dilution, Santa Cruz Biotechnology, Santa Cruz, CA,
USA). β-actin (Sigma-Aldrich, St. Louis, MO, USA) was
used as a loading control in the western blot.
ELISA
The concentration of p53 in the treated and untreated
tissues was determined using p53 Abs ELISA kit [25]
(Medical & Biological Laboratories Co. Ltd., Nagoya,
Japan). The concentration of VEGF in the treated and
untreated tissues was determined using an ELISA kit with
the antibodies which recognize VEGF165 [26] (R&D Sys-
tems Inc., Minneapolis, USA). Glyceraldehyde-3-phosphate
dehydrogenase hybridization was used as a loading control.
Statistical analysis
The statistic differences between two means were com-
pared by one-way analysis of variance (ANOVA). Fisher’s
least significant difference test was used as post hoc tests
of significant differences between two parameters. Data
was analyzed using StatView 5.0 software (Abacus sys-
tems, Berkley, CA, USA) with a P value of <0.05 accepted
as significant.Results
The effects of I-125 implant on tumor volume
Before the I-125 seed implant, the tumor volumes were al-
most the same. After the seed implant, the tumor volume
in the 0.8 mCi group was reduced by up to 40% compared
with those from the controls with 0 mCi (Figure 1); the
difference was significant (P <0.001). The effective in-
hibition dosage of I-125 ranged from 0.4 to 0.8 mCi
(Figure 1).
Inhibitory rate of different dosages
The weight of the different tumors was 5.26 ± 0.31,
5.27 ± 0.25, 4.13 ± 0.13, 3.47 ± 0.17, and 2.83 ± 0.16 g in
blank, 0, 0.2, 0.4, and 0.8 mCi groups, respectively, giv-
ing a respective growth inhibition of 0, 21.5%, 34.0%,
and 46.2%. Thus, the 0.8 mCi I-125 dosage showed ef-
fective inhibitory results for CRC.
The assay for apoptosis
The apoptosis was visualized in the tumors treated with
I-125 under an oil microscope. According to a previous
report, brown colored positive apoptotic cells were ob-
served and normal cells were in a blue color with the
TUNEL method [27]. Figure 2A shows that the nuclei
were colored blue in the normal cancer cell. Five days
after the I-125 seed implantation, the nuclei were stained
a brown color with decreased expression of PCNA in
apoptosis cells while the nuclei were of a normal color
in the 0 mCi group (Figure 2B1 and B2). Fifteen days
after I-125 seed implantation, the nuclei disappeared be-
cause of the emerging destructive stage of apoptosis,
while a few cells showed apoptosis in the 0 mCi group
(Figure 2C1 and C2). The TUNEL assay showed normal
colon cells with a blue color while the germination of cells
was found in the 0.8 mCi group (Figure 2D1 and D2).
Figure 2 HCT-8 cell transplanted tumor (HE × 400). (A) Strong positive expression of PCNA protein on different phases after I-125 seed implantation;
(B1) HCT-8 cell transplanted tumor before day 5 in the 0 mCi group (SP × 200); (B2) Day 5 in the 0.8 mCi group (SP × 400); (C1) Day 15 in the 0 mCi group
(SP × 400); (C2) Day 15 in the 0.8 mCi group (SP × 400); (D1) 0 mCi group, a few apoptosis cells were seen, nuclei were stained blue and small nucleoli were
seen; (D2) 0.8 mCi group, characteristic findings of cell apoptosis, germination was observed on day 10; (D3) 0.8 mCi group, vacuolization in the cytoplasm
occurred in the apoptotic cell on day 15.
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cell on day 15 of I-125 implantation (Figure 2D3).The association between MVD and VEGF
The MVD for the five groups was 50.19 ± 21.38, 51.30 ±
20.26, 41.67 ± 17.56, 32.50 ± 10.95, and 22.62 ± 7.14, re-
spectively. The expression of VEGF and MVD was closely
related with the development of CRC. The results sug-
gested that high protein level of VEGF caused high levels
of MVD, which would increase the risk of colon cancer.The association between weights and MVD-VEGF
We guessed that the weight of model mice might be af-
fected by the levels of MVD and VEGF. Thus, the asso-
ciation between the weight and levels of MVD-VEGF
was investigated here. The Spearman’s rank correlation
coefficient for the association between the weigh and the
levels of MCD or VEGF in the tumors was 0.85 and
0.72, respectively. Both P values were less than 0.01. The
results suggested that the weight was strongly related
with the levels of MVD or VEGF.Figure 3 Western blotting analyses for the relative protein levels of p5
was used as a loading control. Each bar represented the mean ± SD of threThe relative protein levels of p53 and VEGF
Compared with the control group, the expression level
of p53 was up-regulated when it was treated by I-125
seeds from low- to high-dosage (Figure 3), suggesting
that I-125 can increase the expression level of p53. p53
is an important cancer repressor [28], and thus the
mechanism of iodine inhibition of CRC growth acts
through activation of the levels of p53. Inversely, com-
paring the control group, the expression of VEGF was
down-regulated when it was treated by I-125 from low-
to high-dosage (Figure 3), suggesting that I-125 can re-
duce the expression of VEGF. Anti-VEGF has been stud-
ies in clinical trials for cancer therapy [29]; thus, iodine
treatment is a better method for inhibiting the growth of
CRC via the activation of anti-VEGF.The concentration of p53 and VEGF
Compared with the control group, the concentration of
p53 reached the highest level when the rats were treated
with I-125 at the highest dosage (Figure 4), suggesting
that I-125 can increase the concentration of p53. Just as
analyzed by western blotting, p53 was an important3 and VEGF in 0, 0.2, 0.4, and 0.8 mCi I-125-treated groups. β-actin
e independent experiments.
Figure 4 The concentration of p53 and VEGF in 0, 0.2, 0.4, and 0.8 mCi I-125 treated groups determined by ELISA. Each bar represented
the mean ± SD of three independent experiments.
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the growth of CRC was to increase the level of p53. In-
versely, compared with the control group, the concentra-
tion of VEGF was reduced to the lowest level when it was
treated by I-125 at the highest dosage (Figure 4), suggest-
ing that I-125 can reduce the concentration of VEGF.
Discussion
Cancer is a leading cause of death in the world and I-125
radiation therapy has proved effective in the treatment of
various carcinomas [30-34]. The theoretical benefit of seed
permanent implantation as a salvage treatment is to en-
hance disease control in the region of recurrence and to
minimize the injury to the surrounding tissues [35,36].
However, the molecular mechanisms for I-125 inhibiting
CRC are widely unknown. We were therefore interested
to explore said mechanisms. Herein, we gained significant
results in using I-125 seed implantation to treat CRC mice
models. We firstly reported the molecular mechanisms in-
volved in the inhibition of CRC by I-125, mainly showing
that a suitable dosage of I-125 can increase the expression
of p53, which inhibits the expression of VEGF and causes
lower MVD, leading to the cell apoptosis. The findings
also indicated that MVD and VEGF were reliable com-
bined predictors of prognosis in CRC. On the other hand,
these findings support the hypothesis that VEGF is an im-
portant angiogenic factor in primary and metastatic hu-
man CRC. VEGF expression and vessel counts might aid
in predicting patients at risk for metastasis from CRC,
which is consistent with previous reports [37,38].
Regarding the tumor apoptosis caused by I-125 treat-
ment, one important issue remains uncertain, namely
that Figure 2D2, D3 is not completely clear and thus
apoptosis may be confounded with mitotic death and
pre-micronuclei formation. However, apoptosis can be
evaluated by peroxidase-TUNEL (brown) counterstained
with hematoxylin (blue) [39]. Thus, we still thought I-125
treatment caused the apoptosis of CRC but not mitoticdeath and pre-micronuclei formation since the nuclei were
a brown color.
Epidemiologic studies have consistently reported posi-
tive associations between the weight and CRC risk for
adults [40-42]. Achieving optimum BMI levels and
weight reduction in the population appears to offer the
greatest health benefits and decrease the risk of CRC
[43,44]. Herein, we found that the I-125 treatment re-
sulted in mice weight loss, which was the main reason
for I-125 controlling the development of CRC. Thus,
the molecular mechanisms for I-125 inhibiting CRC
were that I-125 treatment increases the expression of
p53 and reduces the expression of VEGF, which leads
to a decrease of MVD. All the parameters were closely
related with the weights of the mice models. The infor-
mation should be beneficial to improve the treatment
of various cancers with iodine.
The efficacy of iodine in treating various cancers is ob-
vious [45-47], but its adverse effects are also protruding
[48,49]. Even though the risk of I-125 for persistent side
effects is rather small, these data do emphasize the need
to carefully select the patients for I-125 treatment. The
CRC patients who are thought to be at moderate to high
risk for recurrence, should use the minimally effective
dose of I-125 activity, in an attempt to maximize the po-
tential benefit while minimizing the risk for adverse
events. Here, we found that the effective inhibition dos-
age of I-125 ranged from 0.4 to 0.8 mCi. The results
offer important information for subsequent clinical trials
and will be beneficial to utilize the iodine therapy tech-
niques effectively and safely. Considering the side effects
of I-125, controlled trials with a larger sample size and
longer follow-up are recommended in the future.
Conclusions
In summary, we established animal models of CRC via the
injection of HCT-8 cells into nude mice. Subsequently,
the I-125 granules were implanted into the tumor of the
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were used to detect apoptosis of the tumor cells. I-125
protests against CRC via increasing the protein level of
p53 and decreasing the level of VEGF, which leads to the
decrease of MVD in CRC. An effective inhibition dosage
of I-125 ranged from 0.4 to 0.8 mCi.
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